JP2009106750A - フィラメント補強されたコンポジットファイバー - Google Patents
フィラメント補強されたコンポジットファイバー Download PDFInfo
- Publication number
- JP2009106750A JP2009106750A JP2008277318A JP2008277318A JP2009106750A JP 2009106750 A JP2009106750 A JP 2009106750A JP 2008277318 A JP2008277318 A JP 2008277318A JP 2008277318 A JP2008277318 A JP 2008277318A JP 2009106750 A JP2009106750 A JP 2009106750A
- Authority
- JP
- Japan
- Prior art keywords
- reinforced composite
- composite fiber
- filament
- filament reinforced
- filaments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000835 fiber Substances 0.000 title claims abstract description 164
- 239000002131 composite material Substances 0.000 title claims abstract description 155
- 239000011159 matrix material Substances 0.000 claims abstract description 50
- 239000000853 adhesive Substances 0.000 claims abstract description 33
- 230000001070 adhesive effect Effects 0.000 claims abstract description 33
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- -1 ester amide Chemical class 0.000 claims description 38
- 229920000642 polymer Polymers 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 16
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims description 14
- 229920001577 copolymer Polymers 0.000 claims description 14
- 229920001651 Cyanoacrylate Polymers 0.000 claims description 13
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 claims description 12
- 239000000178 monomer Substances 0.000 claims description 11
- 230000002745 absorbent Effects 0.000 claims description 10
- 239000002250 absorbent Substances 0.000 claims description 10
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 10
- 102000008186 Collagen Human genes 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims description 8
- 239000004743 Polypropylene Substances 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 7
- 229920001155 polypropylene Polymers 0.000 claims description 7
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 6
- 238000012377 drug delivery Methods 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 6
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 6
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 230000003872 anastomosis Effects 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- RPQUGMLCZLGZTG-UHFFFAOYSA-N octyl cyanoacrylate Chemical compound CCCCCCCCOC(=O)C(=C)C#N RPQUGMLCZLGZTG-UHFFFAOYSA-N 0.000 claims description 5
- 229920001451 polypropylene glycol Polymers 0.000 claims description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 229920000431 shape-memory polymer Polymers 0.000 claims description 4
- SJDLIJNQXLJBBE-UHFFFAOYSA-N 1,4-dioxepan-2-one Chemical compound O=C1COCCCO1 SJDLIJNQXLJBBE-UHFFFAOYSA-N 0.000 claims description 3
- AOLNDUQWRUPYGE-UHFFFAOYSA-N 1,4-dioxepan-5-one Chemical compound O=C1CCOCCO1 AOLNDUQWRUPYGE-UHFFFAOYSA-N 0.000 claims description 3
- ALRHLSYJTWAHJZ-UHFFFAOYSA-M 3-hydroxypropionate Chemical compound OCCC([O-])=O ALRHLSYJTWAHJZ-UHFFFAOYSA-M 0.000 claims description 3
- PFSVSOOFNDBGMO-UHFFFAOYSA-N 3-methoxypropyl 2-cyanoprop-2-enoate Chemical compound COCCCOC(=O)C(=C)C#N PFSVSOOFNDBGMO-UHFFFAOYSA-N 0.000 claims description 3
- FMHKPLXYWVCLME-UHFFFAOYSA-N 4-hydroxy-valeric acid Chemical compound CC(O)CCC(O)=O FMHKPLXYWVCLME-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 3
- 108010073385 Fibrin Proteins 0.000 claims description 3
- 102000009123 Fibrin Human genes 0.000 claims description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 108090000190 Thrombin Proteins 0.000 claims description 3
- 229920010741 Ultra High Molecular Weight Polyethylene (UHMWPE) Polymers 0.000 claims description 3
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920001971 elastomer Polymers 0.000 claims description 3
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 claims description 3
- 229950010048 enbucrilate Drugs 0.000 claims description 3
- FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 claims description 3
- 229940053009 ethyl cyanoacrylate Drugs 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- QRWOVIRDHQJFDB-UHFFFAOYSA-N isobutyl cyanoacrylate Chemical compound CC(C)COC(=O)C(=C)C#N QRWOVIRDHQJFDB-UHFFFAOYSA-N 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 239000005060 rubber Substances 0.000 claims description 3
- 229960004072 thrombin Drugs 0.000 claims description 3
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 claims description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 2
- 239000002407 tissue scaffold Substances 0.000 claims description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 24
- 238000000034 method Methods 0.000 abstract description 22
- 230000008569 process Effects 0.000 abstract description 4
- 210000001519 tissue Anatomy 0.000 description 31
- 206010052428 Wound Diseases 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000009954 braiding Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000009940 knitting Methods 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 238000009941 weaving Methods 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 239000004952 Polyamide Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229920002647 polyamide Polymers 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 229960003500 triclosan Drugs 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 229910052788 barium Inorganic materials 0.000 description 3
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 3
- 238000005266 casting Methods 0.000 description 3
- 239000011162 core material Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- KHICUSAUSRBPJT-UHFFFAOYSA-N 2-(2-octadecanoyloxypropanoyloxy)propanoic acid Chemical class CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(O)=O KHICUSAUSRBPJT-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000007740 vapor deposition Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- VKSWWACDZPRJAP-UHFFFAOYSA-N 1,3-dioxepan-2-one Chemical compound O=C1OCCCCO1 VKSWWACDZPRJAP-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- GINVCSKBOCDMBE-UHFFFAOYSA-N 2-chloro-1h-hexazine Chemical compound ClN1NN=NN=N1 GINVCSKBOCDMBE-UHFFFAOYSA-N 0.000 description 1
- URDHOZXGQQGHHF-UHFFFAOYSA-N 3-chloro-2,6-dimethylcyclohexa-2,4-dien-1-one Chemical compound ClC1=C(C(C(C=C1)C)=O)C URDHOZXGQQGHHF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 229920003235 aromatic polyamide Polymers 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000003916 calcium stearoyl-2-lactylate Substances 0.000 description 1
- OEUVSBXAMBLPES-UHFFFAOYSA-L calcium stearoyl-2-lactylate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O.CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O OEUVSBXAMBLPES-UHFFFAOYSA-L 0.000 description 1
- 235000010957 calcium stearoyl-2-lactylate Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003733 fiber-reinforced composite Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 150000002241 furanones Chemical class 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003668 hormone analog Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940035535 iodophors Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 150000002680 magnesium Chemical class 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- SERHXTVXHNVDKA-UHFFFAOYSA-N pantolactone Chemical compound CC1(C)COC(=O)C1O SERHXTVXHNVDKA-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000412 polyarylene Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229940076376 protein agonist Drugs 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 229940081192 rifamycins Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 229940071209 stearoyl lactylate Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N vinyl-ethylene Natural products C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L31/129—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/10—At least partially resorbable materials containing macromolecular materials
- A61L17/12—Homopolymers or copolymers of glycolic acid or lactic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/14—Post-treatment to improve physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L29/126—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
- A61B17/06166—Sutures
- A61B2017/06176—Sutures with protrusions, e.g. barbs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T156/00—Adhesive bonding and miscellaneous chemical manufacture
- Y10T156/10—Methods of surface bonding and/or assembly therefor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/24—Structurally defined web or sheet [e.g., overall dimension, etc.]
- Y10T428/24058—Structurally defined web or sheet [e.g., overall dimension, etc.] including grain, strips, or filamentary elements in respective layers or components in angular relation
- Y10T428/24124—Fibers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Composite Materials (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Materials For Medical Uses (AREA)
- Nonwoven Fabrics (AREA)
Abstract
【解決手段】複数のフィラメントおよび接着マトリックス材料を含むフィラメント補強コンポジットファィバーであって、その上の表面に形成された少なくとも1つの一体的なとげを有する、フィラメント補強コンポジットファィバーが提供される。さらに、医療用デバイスを作製する方法であって:複数のフィラメントに接着マトリックス材料を付与する工程であって、フィラメント補強コンポジットファイバーを提供する工程;および該フィラメント補強コンポジットファイバーの表面上に少なくとも1つのとげをコーティングする工程、を包含する、方法が提供される。
【選択図】図5
Description
本出願は、2007年10月29に出願された米国仮特許出願番号第60/983,262号の利益およびそれへの優先権を主張しており、この特許出願の全体の開示は、本明細書中に参考として援用される。
(技術分野)
本開示は、一般に外科用デバイスの分野に関し、そしてより特定すれば、ファイバー、メッシュ、および縫合糸のような移植可能な材料を含む外科用デバイスを形成することにおいて有用なフィラメントで補強されたコンポジットに関する。
外科用縫合糸は、組織および創傷閉鎖を含む種々のタイプの医療手順のために首尾良く用いられている。外科用縫合糸は、種々のサイズおよびタイプ(例えば、モノフィラメントおよび編み組み)で利用可能であり、異なるタイプの組織閉鎖を支持する。外科用縫合糸は、代表的には、1つの端部に取り付けられたニードルを有する。このニードルが組織を貫通するとき、縫合糸は、組織に入り、組織を通過し、そして組織を出て、その点で結ばれ、組織たまは創傷を固定するために用いられ得る。
複数のフィラメントおよびマトリックスから作製されたフィラメント補強コンポジットファイバーは、縫合糸およびメッシュのような医療用デバイスを形成することにおいて有用である。
複数のフィラメント、および接着マトリックス材料を含むフィラメント補強コンポジットファイバーを含み;そして
ここで、該接着マトリックス材料が、該フィラメント補強コンポジットファイバーの全長の少なくとも5%の上に存在し;そして
該フィラメント補強コンポジットファイバーが、その中に結ばれた結び目を有し得る、医療用デバイス。
複数のフィラメントに接着マトリックス材料を付与する工程であって、フィラメント補強コンポジットファイバーを提供する工程;および
該フィラメント補強コンポジットファイバーの表面上に少なくとも1つのとげをコーティングする工程、を包含する、方法。
該フィラメント補強コンポジットファイバーを、組織の第2の部分を通って引く工程;および、該組織を出て創傷閉鎖を生成する工程を提供して創傷を閉じる方法。
創傷を閉じるためのシステムであって、組織の第1の部分を通るように構成されたフィラメント補強コンポジットファイバーと;
該ファイバーが組織を出て創傷閉鎖を生成するように、該フィラメント補強コンポジットファイバーを組織の第2の部分を通って引くための手段と;
を備える、システム。
本開示の第1の局面では、フィラメント補強コンポジットファイバーは、複数のフィラメント、接着マトリックス材料を含み、そしてこのフィラメント補強コンポジットファイバーは、その表面上に形成された少なくとも1つの一体的なとげを有する。実施形態では、このフィラメント補強コンポジットファイバーは、縫合糸として用いられ得るか、またはメッシュ中に取り込まれ得る。
本開示は、フィラメント補強コンポジットファイバーに関する。このフィラメント補強コンポジットファイバーは、接着マトリックス材料と組み合わせて、複数のフィラメントから形成された細長い本体を有する。本開示の実施形態の医療用デバイスは、このフィラメント補強コンポジットファイバーから作製された外科用メッシュおよび外科用縫合糸を含む。
一般に、フィラメントは、約1ミクロン〜約50ミクロン、実施形態では約5ミクロン〜約15ミクロンの直径を有し得る。上記フィラメント補強コンポジットファイバーを形成するために適切な個々のフィラメントは、任意のフィイバーを形成する合成または天然材料、例えば、ポリマーおよび金属(例えば、マグネシウム誘導体、スチールおよびチタン)に由来し得る。これらフィイバー形成材料は、生体吸収性または生体非吸収性であり得る。異なる材料(例えば、天然もしくは合成、または生体吸収性もしくは生体非吸収性の材料)から作製されたフィラメントの組み合わせが、本発明のフィラメント補強コンポジットファイバーを作製するために用いられ得る。
PolysorbTMマルチフィラメント吸収性縫合糸を、オクチルシアノアクリレート中に浸漬した。このシアノアクリレートを硬化させ、フィラメント補強コンポジットファイバー縫合糸を提供した。シアノアクリレートが、編み組みのフィラメントが一緒に結合されるシアノアクリレートマトリックス材料内に包埋され、密着したコンポジットファイバーを生成するように、編み組まれた縫合糸の間隙の間に貫通された。とげを、ナイフブレードを用い、フィラメント補強コンポジットファイバーに沿って規則的な間隔をあけて手で切断した。
PolysorbTMマルチフィラメント吸収性縫合糸を、塩化メチレン中、2wt%トリクロサン溶液中に浸漬した。縫合糸を乾燥させ、そして塩化メチレンを溶媒蒸発し、編み組まれた縫合糸上にトリクロサン堆積物を得た。次いで、縫合糸をオクチルシアノアクリレート中に浸漬した。シアノアクリレートを硬化させ、フィラメント補強コンポジットファイバー縫合糸を提供した。シアノアクリレートが、編み組みのフィラメントが一緒に結合されるシアノアクリレートマトリックス材料内に包埋され、密着したコンポジットファイバーを生成するように、編み組まれた縫合糸の間隙の間に貫通された。とげを、ナイフブレードを用い、コンポジットマルチフィラメント縫合糸に沿って規則的な間隔をあけて手で切断した。サンプルを、抑止ゾーン(ZOI)を含むさらなる試験に供し、そこでは、上記フィラメント補強コンポジットファイバーは、ZOIを示した。
12 とげ
14 本体
16 ニードル
30 メッシュ
32 とげ
36 とげのない部分
Claims (25)
- 複数のフィラメントおよび接着マトリックス材料を含むフィラメント補強コンポジットファィバーであって、その上の表面に形成された少なくとも1つの一体的なとげを有する、フィラメント補強コンポジットファィバー。
- 前記接着マトリックス材料が、前記フィラメント補強コンポジットの全長の少なくとも5%を構成する、請求項1に記載のフィラメント補強コンポジットファィバー。
- 請求項1に記載のフィラメント補強コンポジットを含む、メッシュ。
- 前記複数のフィラメントの少なくとも1つが、吸収性である、請求項1に記載のフィラメント補強コンポジットファィバー。
- 前記複数のフィラメントの少なくとも1つが、ラクチド、グリコリド、カプロラクトン、バレロラクトン、トリメチレンカーボネート、1,4−ジオキサノン、δ−バレロラクトン、ε−カプロラクトン、1,4−ジオキセパン−2−オン、1,5−ジオキセパン−2−オン、コラーゲン、ガット、ポリマー薬物、エチレングリコール、エチレンオキシド、エステルアミド、γ−ヒドロキシバレレート、β−ヒドロキシプロピオネート、α−ヒドロキシ酸、およびβ−ヒドロキシブテレート、コラーゲン、セルロース、ガット、およびそれらのコポリマーからなる群から選択されるポリマーを含む、請求項4に記載のフィラメント補強コンポジットファィバー。
- 前記複数のフィラメントの少なくとも1つが、非吸収性である、請求項1に記載のフィラメント補強コンポジットファィバー。
- 前記複数のフィラメントの少なくとも1つが、シルク、綿、ゴム、ナイロン、ポリプロピレン、ポリエチレン、超高分子量ポリエチレン(UHMWPE)、ポリエチレンテレフタレート(PET)、およびポリエステルならびにそれらのコポリマーから選択されるポリマーを含む、請求項6に記載のフィラメント補強コンポジットファィバー。
- 前記接着マトリックス材料が、モノマー、オリゴマー、ポリマーからなる群から選択される、請求項1に記載のフィラメント補強コンポジットファィバー。
- 前記接着マトリックス材料が、シアノアクリレート、ウレタン、アクリレート、フィブリン、アルブミン、トロンビン、ゼラチン、タンパク質、多糖、ラクチド、コラーゲン、およびカーボネートからなる群から選択される少なくとも1つのモノマーから形成されるポリマーを含む、請求項1に記載のフィラメント補強コンポジットファィバー。
- 前記マトリックス材料が、メチルシアノアクリレート、エチルシアノアクリレート、ブチルシアノアクリレート、オクチルシアノアクリレート、イソブチルシアノアクリレートおよびメトキシプロピルシアノアクリレートならびにそれらのコポリマーからなる群から選択される少なくとも1つのシアノアクリレートを含む、請求項9に記載のフィラメント補強コンポジットファィバー。
- 前記フィラメント補強コンポジットファィバーが、薬剤を含む、請求項1に記載のフィラメント補強コンポジットファィバー。
- 前記フィラメント補強コンポジットファイバーが、脂肪酸エステルをさらに含む、請求項1に記載のフィラメント補強コンポジットファィバー。
- 前記フィラメント補強コンポジットファイバーが、ポリエチレンオキシド、ポリプロピレンオキシド、ラクチド、グリコリド、およびカプロラクトンならびにそれらのコポリマーからなる群から選択されるコーティングをさらに含む、請求項1に記載のフィラメント補強コンポジットファイバー。
- 前記フィラメント補強コンポジットファイバーが、クリップ、ファスナー、創傷用品、包帯、薬物送達デバイス、吻合リング、ステント、グラフト、カテーテル、組織足場、バットレス、ガーゼ、ラップバンド、テープ、またはリボンである、請求項1に記載のフィラメント補強コンポジットファイバー。
- 前記フィラメント補強コンポジットファイバーが、薬剤をさらに含む、請求項1に記載のフィラメント補強コンポジットファイバー。
- 複数のフィラメント、および接着マトリックス材料を含む縫合糸であって、その上の表面に形成された少なくとも1つの一体的なとげを規定する、縫合糸。
- 少なくとも1つのニードルをさらに含む、請求項16に記載の縫合糸。
- 医療用デバイスであって:
複数のフィラメント、および接着マトリックス材料を含むフィラメント補強コンポジットファイバーを含み;そして
ここで、該接着マトリックス材料が、該フィラメント補強コンポジットファイバーの全長の少なくとも5%の上に存在し;そして
該フィラメント補強コンポジットファイバーが、その中に結ばれた結び目を有し得る、医療用デバイス。 - 前記接着マトリックス材料が、前記フィラメント補強コンポジットファイバーの全長の5%〜95%を構成する、請求項18に記載の医療用デバイス。
- 前記接着マトリックス材料が、前記フィラメント補強コンポジットファイバーの全長の20%〜70%を構成する、請求項18に記載の医療用デバイス。
- 前記フィラメント補強コンポジットファイバーが、縫合糸、メッシュ、クリップ、ファスナー、創傷用品、包帯、薬物送達デバイス、吻合リング、ステント、グラフト、カテーテル、組織操作足場、ガーゼ、ラップバンド、テープ、またはリボンである、請求項18に記載の医療用デバイス。
- 前記フィラメント補強コンポジットファイバーが、薬剤をさらに含む、請求項18に記載の医療用デバイス。
- 前記フィラメント補強コンポジットファイバーが、形状記憶ポリマーを含む、請求項18に記載の医療用デバイス。
- 医療用デバイスを作製する方法であって:
複数のフィラメントに接着マトリックス材料を付与する工程であって、フィラメント補強コンポジットファイバーを提供する工程;および
該フィラメント補強コンポジットファイバーの表面上に少なくとも1つのとげをコーティングする工程、を包含する、方法。 - 創傷を閉じるためのシステムであって、組織の第1の部分を通るように構成されたフィラメント補強コンポジットファイバーと;
該ファイバーが組織を出て創傷閉鎖を生成するように、該フィラメント補強コンポジットファイバーを組織の第2の部分を通って引くための手段と;
を備える、システム。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98326207P | 2007-10-29 | 2007-10-29 | |
US60/983,262 | 2007-10-29 | ||
US12/251,909 | 2008-10-15 | ||
US12/251,909 US20090112236A1 (en) | 2007-10-29 | 2008-10-15 | Filament-Reinforced Composite Fiber |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009106750A true JP2009106750A (ja) | 2009-05-21 |
JP5562546B2 JP5562546B2 (ja) | 2014-07-30 |
Family
ID=40459734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008277318A Active JP5562546B2 (ja) | 2007-10-29 | 2008-10-28 | フィラメント補強されたコンポジットファイバー |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090112236A1 (ja) |
EP (1) | EP2055323B1 (ja) |
JP (1) | JP5562546B2 (ja) |
AU (1) | AU2008237580B2 (ja) |
CA (1) | CA2641891A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011218172A (ja) * | 2010-04-12 | 2011-11-04 | Tyco Healthcare Group Lp | 棘付き医療デバイスおよび方法 |
JP2016513531A (ja) * | 2013-03-15 | 2016-05-16 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | 多成分フィラメントベースの外科メッシュ |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8795332B2 (en) | 2002-09-30 | 2014-08-05 | Ethicon, Inc. | Barbed sutures |
US5931855A (en) | 1997-05-21 | 1999-08-03 | Frank Hoffman | Surgical methods using one-way suture |
US7056331B2 (en) | 2001-06-29 | 2006-06-06 | Quill Medical, Inc. | Suture method |
US20040088003A1 (en) | 2002-09-30 | 2004-05-06 | Leung Jeffrey C. | Barbed suture in combination with surgical needle |
US8100940B2 (en) | 2002-09-30 | 2012-01-24 | Quill Medical, Inc. | Barb configurations for barbed sutures |
US10548592B2 (en) | 2004-05-14 | 2020-02-04 | Ethicon, Inc. | Suture methods and devices |
US20080255612A1 (en) * | 2007-04-13 | 2008-10-16 | Angiotech Pharmaceuticals, Inc. | Self-retaining systems for surgical procedures |
US8777987B2 (en) * | 2007-09-27 | 2014-07-15 | Ethicon, Inc. | Self-retaining sutures including tissue retainers having improved strength |
CA2709328C (en) | 2007-12-19 | 2017-01-03 | Angiotech Pharmaceuticals, Inc. | Self-retaining sutures with heat-contact mediated retainers |
US8916077B1 (en) | 2007-12-19 | 2014-12-23 | Ethicon, Inc. | Self-retaining sutures with retainers formed from molten material |
US8118834B1 (en) | 2007-12-20 | 2012-02-21 | Angiotech Pharmaceuticals, Inc. | Composite self-retaining sutures and method |
ES2602570T3 (es) | 2008-01-30 | 2017-02-21 | Ethicon Llc | Aparato y método para formar suturas de auto-retención |
US8615856B1 (en) | 2008-01-30 | 2013-12-31 | Ethicon, Inc. | Apparatus and method for forming self-retaining sutures |
US8273105B2 (en) | 2008-02-20 | 2012-09-25 | Tyco Healthcare Group Lp | Compound barb medical device and method |
BRPI0907787B8 (pt) | 2008-02-21 | 2021-06-22 | Angiotech Pharm Inc | método para formar uma sutura de autorretenção e aparelho para elevar os retentores em um fio de sutura a um ângulo desejado |
US8641732B1 (en) | 2008-02-26 | 2014-02-04 | Ethicon, Inc. | Self-retaining suture with variable dimension filament and method |
BRPI0911132B8 (pt) | 2008-04-15 | 2021-06-22 | Angiotech Pharm Inc | sutura para ser usada em um procedimento aplicado ao tecido |
CN102065913B (zh) * | 2008-04-24 | 2016-11-23 | 伊西康有限责任公司 | 形状记忆的自固位缝线、生产方法和使用方法 |
US8961560B2 (en) | 2008-05-16 | 2015-02-24 | Ethicon, Inc. | Bidirectional self-retaining sutures with laser-marked and/or non-laser marked indicia and methods |
EP2344045A1 (en) * | 2008-09-16 | 2011-07-20 | Ventralfix, Inc. | Method and apparatus for minimally invasive delivery, tensioned deployment and fixation of secondary material prosthetic devices in patient body tissue, including hernia repair within the patient's herniation site |
ES2717373T3 (es) | 2008-11-03 | 2019-06-20 | Ethicon Llc | Longitud de sutura de auto-retención y dispositivo para usar la misma |
DE102008057216A1 (de) * | 2008-11-06 | 2010-05-12 | Aesculap Ag | Chirurgischer Faden mit Kern-Mantel-Aufbau |
DE102009020901A1 (de) * | 2009-05-08 | 2010-11-11 | Aesculap Ag | Beschichteter Faden mit Verankerungsstrukturen zur Verankerung in biologischen Geweben |
DE102009020897A1 (de) * | 2009-05-08 | 2010-11-11 | Aesculap Ag | Faden mit beschichteten Verankerungsstrukturen zur Verankerung in biologischen Geweben und ein Verfahren zu seiner Herstellung |
DE102009020894A1 (de) * | 2009-05-08 | 2010-11-11 | Aesculap Ag | Elastomerer Faden mit Verankerungsstrukturen zur Verankerung in biologischen Geweben |
US10265435B2 (en) | 2009-08-27 | 2019-04-23 | Silver Bullet Therapeutics, Inc. | Bone implant and systems and coatings for the controllable release of antimicrobial metal ions |
US9114197B1 (en) | 2014-06-11 | 2015-08-25 | Silver Bullett Therapeutics, Inc. | Coatings for the controllable release of antimicrobial metal ions |
WO2011031548A2 (en) | 2009-08-27 | 2011-03-17 | Silver Bullet Therapeutics, Inc. | Bone implants for the treatment of infection |
US9821094B2 (en) | 2014-06-11 | 2017-11-21 | Silver Bullet Therapeutics, Inc. | Coatings for the controllable release of antimicrobial metal ions |
US8771323B2 (en) | 2010-11-12 | 2014-07-08 | Silver Bullet Therapeutics, Inc. | Bone implant and systems that controllably releases silver |
US8927004B1 (en) | 2014-06-11 | 2015-01-06 | Silver Bullet Therapeutics, Inc. | Bioabsorbable substrates and systems that controllably release antimicrobial metal ions |
US8690960B2 (en) * | 2009-11-24 | 2014-04-08 | Covidien Lp | Reinforced tissue patch |
US9878487B2 (en) * | 2010-03-03 | 2018-01-30 | Syracuse University | Multi-shape product |
US20110238094A1 (en) * | 2010-03-25 | 2011-09-29 | Thomas Jonathan D | Hernia Patch |
CN103096816B (zh) | 2010-05-04 | 2016-10-12 | 伊西康有限责任公司 | 用于产生自固位缝线的激光切割系统和方法 |
MX337815B (es) | 2010-06-11 | 2016-03-18 | Ethicon Llc | Herramientas para dispensar suturas para cirugía endoscópica y asistida por robot y métodos. |
US8900616B2 (en) | 2010-10-22 | 2014-12-02 | Covidien Lp | System and method for satellite drug delivery |
KR101175135B1 (ko) * | 2010-11-02 | 2012-08-20 | (주)인튜이티브메디코프 | 폴리옥틸시아노아크릴레이트를 이용하여 제조한 봉합사 및 그 제조방법 |
NZ610341A (en) | 2010-11-03 | 2015-05-29 | Tissuegen Inc | Drug-eluting self-retaining sutures and methods relating thereto |
NZ704802A (en) | 2010-11-09 | 2015-12-24 | Ethicon Llc | Emergency self-retaining sutures and packaging |
JP6125488B2 (ja) | 2011-03-23 | 2017-05-10 | エシコン・エルエルシーEthicon LLC | 自己保持可変ループ縫合材 |
US20130172931A1 (en) | 2011-06-06 | 2013-07-04 | Jeffrey M. Gross | Methods and devices for soft palate tissue elevation procedures |
US8715334B2 (en) | 2011-07-14 | 2014-05-06 | Boston Scientific Scimed, Inc. | Anti-migration stent with quill filaments |
US8932623B2 (en) * | 2011-08-25 | 2015-01-13 | Ethicon, Inc. | Protective wound dressing device for oral and pharyngeal space |
BR112014008220A2 (pt) * | 2011-10-05 | 2017-04-11 | Smith & Nephew | dispositivos médicos que contêm composições de polímeros com memória de forma |
US20150031772A1 (en) * | 2012-02-17 | 2015-01-29 | Bacterin International, Inc. | Adjustable bioactive agent dispersion within a polymeric coating |
DE102012005978A1 (de) * | 2012-03-23 | 2013-09-26 | Johnson & Johnson Medical Gmbh | Chirurgisches Implantat |
US9662018B2 (en) * | 2012-03-30 | 2017-05-30 | Covidien Lp | Integrated self-fixating visualization devices, systems and methods |
US9415137B2 (en) | 2012-08-22 | 2016-08-16 | Biomet Manufacturing, Llc. | Directional porous coating |
WO2014084853A1 (en) * | 2012-11-30 | 2014-06-05 | Empire Technology Development Llc | Magnetothermal fibers |
US9775928B2 (en) | 2013-06-18 | 2017-10-03 | Covidien Lp | Adhesive barbed filament |
US9452242B2 (en) | 2014-06-11 | 2016-09-27 | Silver Bullet Therapeutics, Inc. | Enhancement of antimicrobial silver, silver coatings, or silver platings |
US10806819B2 (en) * | 2015-01-15 | 2020-10-20 | Marshall University Research Corporation | Wound coverings comprising vitamin d and related methods |
US10238481B2 (en) * | 2016-09-20 | 2019-03-26 | Surgical Innovation Associates, Inc. | Apparatus and method for lifting or restraining a body part |
JP7469880B2 (ja) * | 2017-06-13 | 2024-04-17 | 株式会社カネカ | 生体内留置チューブ |
EP3697338A1 (en) | 2017-10-19 | 2020-08-26 | C.R. Bard, Inc. | Self-gripping hernia prosthesis |
CN107595339A (zh) * | 2017-11-01 | 2018-01-19 | 武汉医佳宝生物材料有限公司 | 一种带加固型倒刺的手术缝合线 |
CA3091619C (en) * | 2018-01-31 | 2023-02-28 | Limited Liability Company "Elastic Titanium Implants" | Composite surgical suture material based on polyfilament titanium thread and bioresorbable polymers |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0413690U (ja) * | 1990-05-25 | 1992-02-04 | ||
JPH0551818A (ja) * | 1990-07-27 | 1993-03-02 | Kuraray Co Ltd | 吸水性のすぐれた不織布 |
JPH0998837A (ja) * | 1995-10-09 | 1997-04-15 | Shiseido Co Ltd | ブラシのブリッスル用繊維 |
US6264675B1 (en) * | 2000-02-04 | 2001-07-24 | Gregory R. Brotz | Single suture structure |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3123077A (en) * | 1964-03-03 | Surgical suture | ||
US2280603A (en) * | 1939-07-19 | 1942-04-21 | Armour & Co | Preparing suture materials |
US3187752A (en) * | 1962-04-27 | 1965-06-08 | American Cyanamid Co | Non-absorbable silicone coated sutures and method of making |
US3272204A (en) * | 1965-09-22 | 1966-09-13 | Ethicon Inc | Absorbable collagen prosthetic implant with non-absorbable reinforcing strands |
US3454011A (en) * | 1966-12-28 | 1969-07-08 | Marvin Wagner | Sutures and prosthetic patches |
US3540452A (en) * | 1968-02-28 | 1970-11-17 | Dow Chemical Co | Suture |
US3565077A (en) * | 1968-05-06 | 1971-02-23 | American Cyanamid Co | Densified absorbably polyglycolic acid suture braid, and method for preparing same |
JPS494559B1 (ja) * | 1970-08-06 | 1974-02-01 | ||
US3791388A (en) * | 1971-09-22 | 1974-02-12 | Ethicon Inc | Covered suture |
US3847156A (en) * | 1972-07-17 | 1974-11-12 | Sherwood Medical Ind Inc | Suture |
US3991766A (en) * | 1973-05-31 | 1976-11-16 | American Cyanamid Company | Controlled release of medicaments using polymers from glycolic acid |
US4027676A (en) * | 1975-01-07 | 1977-06-07 | Ethicon, Inc. | Coated sutures |
US4024871A (en) * | 1975-07-23 | 1977-05-24 | Ethicon, Inc. | Antimicrobial sutures |
US4104973A (en) * | 1975-08-13 | 1978-08-08 | Dwyer John R | Method and apparatus for displaying bread in supermarkets |
US4043344A (en) * | 1976-09-20 | 1977-08-23 | American Cyanamid Company | Non-absorbable surgical sutures coated with polyoxyethylene-polyoxypropylene copolymer lubricant |
US4047533A (en) * | 1976-09-20 | 1977-09-13 | American Cyanamid Company | Absorbable surgical sutures coated with polyoxyethylene-polyoxypropylene copolymer lubricant |
GB1575527A (en) * | 1976-12-20 | 1980-09-24 | Johnson & Johnson | Material detectable by x-rays |
FR2439003A1 (fr) * | 1978-10-20 | 1980-05-16 | Anvar | Nouvelles pieces d'osteosynthese, leur preparation et leur application |
FI75493C (fi) * | 1985-05-08 | 1988-07-11 | Materials Consultants Oy | Sjaelvarmerat absorberbart osteosyntesmedel. |
US5261886A (en) * | 1987-08-26 | 1993-11-16 | United States Surgical Corporation | Cabled core and braided suture made therefrom |
US5306289A (en) * | 1987-08-26 | 1994-04-26 | United States Surgical Corporation | Braided suture of improved characteristics |
US5019093A (en) * | 1989-04-28 | 1991-05-28 | United States Surgical Corporation | Braided suture |
US5226912A (en) * | 1987-08-26 | 1993-07-13 | United States Surgical Corporation | Combined surgical needle-braided suture device |
US5100422A (en) * | 1989-05-26 | 1992-03-31 | Impra, Inc. | Blood vessel patch |
US5133738A (en) * | 1989-09-27 | 1992-07-28 | United States Surgical Corporation | Combined surgical needle-spiroid braided suture device |
US5059213A (en) * | 1990-03-26 | 1991-10-22 | United States Surgical Corporation | Spiroid braided suture |
US5181923A (en) * | 1990-03-26 | 1993-01-26 | United States Surgical Corporation | Spiroid braided suture |
US5236563A (en) * | 1990-06-18 | 1993-08-17 | Advanced Surface Technology Inc. | Surface-modified bioabsorbables |
ATE115464T1 (de) * | 1990-06-29 | 1994-12-15 | Flexline Services Ltd | Verfahren zur herstellung von verstärktem verbundmaterial und ein fasermaterial zur benutzung während dieses verfahrens. |
US5370031A (en) * | 1990-08-17 | 1994-12-06 | United States Surgical Corporation | Braider apparatus with improved bobbin holder |
CA2048464A1 (en) * | 1990-08-17 | 1992-02-18 | Michael P. Chesterfield | Apparatus and method for producing braided suture products |
CA2053642C (en) * | 1990-12-13 | 2003-12-30 | George R. Proto | Method and apparatus for tipping sutures |
US5383925A (en) * | 1992-09-14 | 1995-01-24 | Meadox Medicals, Inc. | Three-dimensional braided soft tissue prosthesis |
US5318575A (en) * | 1992-02-03 | 1994-06-07 | United States Surgical Corporation | Method of using a surgical repair suture product |
US5385579A (en) * | 1993-03-30 | 1995-01-31 | Siemens Pacesetter, Inc. | Myocardial body implantable lead |
US5342376A (en) * | 1993-05-03 | 1994-08-30 | Dermagraphics, Inc. | Inserting device for a barbed tissue connector |
US6241747B1 (en) * | 1993-05-03 | 2001-06-05 | Quill Medical, Inc. | Barbed Bodily tissue connector |
US8795332B2 (en) * | 2002-09-30 | 2014-08-05 | Ethicon, Inc. | Barbed sutures |
US6315788B1 (en) * | 1994-02-10 | 2001-11-13 | United States Surgical Corporation | Composite materials and surgical articles made therefrom |
EP0767819A4 (en) * | 1994-06-28 | 1997-09-24 | Tri Point Medical Corp | PH-MODIFIED, BIO-COMPATIBLE MONOMER AND POLYMER COMPOSITION |
US5582616A (en) * | 1994-08-05 | 1996-12-10 | Origin Medsystems, Inc. | Surgical helical fastener with applicator |
US5741332A (en) * | 1995-01-23 | 1998-04-21 | Meadox Medicals, Inc. | Three-dimensional braided soft tissue prosthesis |
US5772640A (en) * | 1996-01-05 | 1998-06-30 | The Trustees Of Columbia University Of The City Of New York | Triclosan-containing medical devices |
US5667528A (en) * | 1995-11-22 | 1997-09-16 | United States Surgical Corporation | Braided suture surgical incision member attachment |
US5728135A (en) * | 1996-02-09 | 1998-03-17 | Ethicon, Inc. | Stiffened suture for use in a suturing device |
US6063105A (en) * | 1996-06-18 | 2000-05-16 | United States Surgical | Medical devices fabricated from elastomeric alpha-olefins |
US5786022A (en) * | 1996-10-31 | 1998-07-28 | Ethicon, Inc. | Coating mixture for surgical articles |
US5931855A (en) * | 1997-05-21 | 1999-08-03 | Frank Hoffman | Surgical methods using one-way suture |
US6692499B2 (en) * | 1997-07-02 | 2004-02-17 | Linvatec Biomaterials Oy | Surgical fastener for tissue treatment |
US6203564B1 (en) * | 1998-02-26 | 2001-03-20 | United States Surgical | Braided polyester suture and implantable medical device |
US6165202A (en) * | 1998-07-06 | 2000-12-26 | United States Surgical Corporation | Absorbable polymers and surgical articles fabricated therefrom |
US6183499B1 (en) * | 1998-09-11 | 2001-02-06 | Ethicon, Inc. | Surgical filament construction |
US6235869B1 (en) * | 1998-10-20 | 2001-05-22 | United States Surgical Corporation | Absorbable polymers and surgical articles fabricated therefrom |
US6733450B1 (en) * | 2000-07-27 | 2004-05-11 | Texas Systems, Board Of Regents | Therapeutic methods and apparatus for use of sonication to enhance perfusion of tissue |
US6620846B1 (en) * | 2000-08-02 | 2003-09-16 | Closure Medical Corporation | Absorbable adhesive compositions |
EP1309279A4 (en) * | 2000-08-17 | 2008-04-09 | Tyco Healthcare | US SUTURES AND COATINGS FROM RESORBABLE THERAPEUTIC GLASS |
EP1372746A2 (en) * | 2001-03-26 | 2004-01-02 | Tyco Healthcare Group Lp | Polyolefin sutures having improved processing and handling characteristics |
US6599310B2 (en) * | 2001-06-29 | 2003-07-29 | Quill Medical, Inc. | Suture method |
US7087060B2 (en) * | 2001-07-20 | 2006-08-08 | Trustees Of The University Of Pennsylvania | Methods for obtaining hemostasis of percutaneous wounds |
CN100463704C (zh) * | 2001-09-24 | 2009-02-25 | 斯科特实验室公司 | 集成药物输送系统 |
US20030097148A1 (en) * | 2001-11-20 | 2003-05-22 | Tero Valimaa | Tissue fastener |
US20030149447A1 (en) * | 2002-02-01 | 2003-08-07 | Morency Steven David | Barbed surgical suture |
US6773450B2 (en) * | 2002-08-09 | 2004-08-10 | Quill Medical, Inc. | Suture anchor and method |
US8100940B2 (en) * | 2002-09-30 | 2012-01-24 | Quill Medical, Inc. | Barb configurations for barbed sutures |
US20040088003A1 (en) * | 2002-09-30 | 2004-05-06 | Leung Jeffrey C. | Barbed suture in combination with surgical needle |
US20040153125A1 (en) * | 2002-12-13 | 2004-08-05 | Mark Roby | Antimicrobial fatty acid containing suture coating |
US10548592B2 (en) * | 2004-05-14 | 2020-02-04 | Ethicon, Inc. | Suture methods and devices |
US20060233852A1 (en) * | 2005-04-19 | 2006-10-19 | Promethean Surgical Devices | Prosthetic for tissue reinforcement |
US20070050018A1 (en) * | 2005-09-01 | 2007-03-01 | John Wainwright | Biodegradable stents |
US20080051834A1 (en) * | 2006-08-28 | 2008-02-28 | Mazzocca Augustus D | High strength suture coated with collagen |
US8353931B2 (en) * | 2006-11-02 | 2013-01-15 | Covidien Lp | Long term bioabsorbable barbed sutures |
-
2008
- 2008-10-15 US US12/251,909 patent/US20090112236A1/en not_active Abandoned
- 2008-10-27 CA CA002641891A patent/CA2641891A1/en not_active Abandoned
- 2008-10-27 EP EP08253488A patent/EP2055323B1/en active Active
- 2008-10-28 JP JP2008277318A patent/JP5562546B2/ja active Active
- 2008-10-29 AU AU2008237580A patent/AU2008237580B2/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0413690U (ja) * | 1990-05-25 | 1992-02-04 | ||
JPH0551818A (ja) * | 1990-07-27 | 1993-03-02 | Kuraray Co Ltd | 吸水性のすぐれた不織布 |
JPH0998837A (ja) * | 1995-10-09 | 1997-04-15 | Shiseido Co Ltd | ブラシのブリッスル用繊維 |
US6264675B1 (en) * | 2000-02-04 | 2001-07-24 | Gregory R. Brotz | Single suture structure |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011218172A (ja) * | 2010-04-12 | 2011-11-04 | Tyco Healthcare Group Lp | 棘付き医療デバイスおよび方法 |
JP2016513531A (ja) * | 2013-03-15 | 2016-05-16 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | 多成分フィラメントベースの外科メッシュ |
Also Published As
Publication number | Publication date |
---|---|
AU2008237580B2 (en) | 2014-05-22 |
EP2055323A3 (en) | 2011-08-24 |
JP5562546B2 (ja) | 2014-07-30 |
EP2055323B1 (en) | 2013-03-20 |
EP2055323A2 (en) | 2009-05-06 |
US20090112236A1 (en) | 2009-04-30 |
CA2641891A1 (en) | 2009-04-29 |
AU2008237580A1 (en) | 2009-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5562546B2 (ja) | フィラメント補強されたコンポジットファイバー | |
JP5570045B2 (ja) | 繋留縫合糸 | |
US8932327B2 (en) | Anchoring device | |
JP5656363B2 (ja) | 手術縫合糸配置システム | |
CA2599929C (en) | Bioactive substance in a barbed suture | |
US11007296B2 (en) | Drug-eluting self-retaining sutures and methods relating thereto | |
CA2781107C (en) | Braided self-retaining sutures and methods | |
EP2566399B1 (en) | Surface texture configuration for self-retaining sutures | |
US20080195147A1 (en) | Surface eroding barbed sutures |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120723 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130704 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131003 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131204 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140303 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140306 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140328 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140501 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140605 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140611 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5562546 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |